Researchers from the University of Cambridge and Yale University discovered that two different brain circuits control appetite using the same receptor [1, 2].
This finding explains why different pharmacological strategies targeting the same receptor can both result in weight loss. By identifying these distinct pathways, scientists may be able to refine the development of obesity medications to maximize efficacy and reduce side effects.
The research, published in Nature Metabolism in July 2026 [1], focused on the GIP receptor. Scientists found that activating this receptor in the brainstem suppresses appetite [3]. Conversely, blocking the same receptor in the hypothalamus enhances satiety [1, 3].
This discovery resolves a long-standing contradiction in metabolic research. Previously, it was unclear why both the stimulation and the blockade of a single "switch" in the brain could promote weight loss [4]. The teams determined that the effect depends entirely on which neural circuit is being engaged.
The study utilized mouse experiments to map these interactions [3]. The results suggest that the mechanism behind some modern weight-loss medications is more complex than previously understood. For example, semaglutide, the active ingredient in Ozempic, may rely on an unexpected group of brain cells to achieve its effects [5].
By isolating the roles of the brainstem and the hypothalamus, the researchers have provided a mechanistic explanation for contradictory drug behaviors. This suggests that future treatments could be tailored to target specific circuits rather than the receptor globally [1, 3].
“Cambridge scientists have solved the mystery of why both stimulating and blocking a particular 'switch' in the brain can help people lose weight.”
The identification of region-specific responses to the GIP receptor suggests that the 'one-size-fits-all' approach to metabolic drugs may be inefficient. If weight loss can be triggered by either activating or blocking a receptor depending on the brain region, future pharmaceutical design may shift toward site-specific targeting to optimize satiety while minimizing systemic side effects.
